

Special Issue

Aging and Hematological Neoplasms

Message from the Guest Editor

Most hematological neoplasms are predominantly diseases of older adults. Aging plays an important role in disease initiation and progression. Clonally restricted hematopoiesis is a common aging-associated biological state that predisposes to the development of a hematological malignancy. Potential drivers of progression from precursor states to overt neoplasia including secondary mutations in clonal cells, altered transcriptional program, marrow microenvironment inflammatory changes and immune exhaustion are also related to aging. Given the aging population and the concomitant increase in the number of older adults with cancer, the need to incorporate geriatric assessment into the care of elderly patients with hematological neoplasms is increasingly being recognized. Although significant progress has been made in recent years due to novel agents and strategies, these patients represent a group with the highest unmet medical need. The aim of this Special Issue is to address the complex relationship between aging and hematological neoplasms, including both biological and pathogenetic aspects as well as clinical and therapeutic challenges.

Guest Editor

Dr. Salvatrice Mancuso

Section of Hematology, Department of Health Promotion Sciences, Maternal and Infantile Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, Italy

Deadline for manuscript submissions

closed (31 March 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/109924

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).